Ten-day decitabine vs “3+7” in patients with AML aged ≥60 years: long-term results of the randomized phase 3 EORTC trial AML21

Blood Neoplasia · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles